Roche Inks Exclusive Worldwide License With Rona Therapeutics for ALK7‑Targeting RNAi Candidate – Up to USD 1.16 Billion Deal Advances Genetically Validated Obesity Target via Extrahepatic Delivery
CompanyDeals

Roche Inks Exclusive Worldwide License With Rona Therapeutics for ALK7‑Targeting RNAi Candidate – Up to USD 1.16 Billion Deal Advances Genetically Validated Obesity Target via Extrahepatic Delivery

Roche (SWX: ROP; OTCMKTS: RHHBY) announced an exclusive worldwide licensing agreement with Rona Therapeutics to develop an investigational RNA interference (RNAi) candidate targeting activin receptor‑like kinase 7 (ALK7), built on…

Sinocelltech's SCT810 Injection Wins NMPA Clearance for Phase I/II Study – Anti‑TFPI Antibody Offers Factor‑Independent Prophylaxis for Hemophilia A and B With or Without Inhibitors
CompanyDrug

Sinocelltech’s SCT810 Injection Wins NMPA Clearance for Phase I/II Study – Anti‑TFPI Antibody Offers Factor‑Independent Prophylaxis for Hemophilia A and B With or Without Inhibitors

Insilico Medicine Nominates ISM9546 as Preclinical Candidate – Oral, Peripherally Restricted VAV1 Molecular Glue Degrader Targets IBD and Rheumatoid Arthritis
CompanyR&D

Insilico Medicine Nominates ISM9546 as Preclinical Candidate – Oral, Peripherally Restricted VAV1 Molecular Glue Degrader Targets IBD and Rheumatoid Arthritis

Lepu Scientech's MemoCarna Oxide Film Single‑Rivet PFO Occluder Approved for Market Launch by NMPA – Novel Design Targets Residual Shunts in Patent Foramen Ovale Closure
CompanyMedical Device

Lepu Scientech’s MemoCarna Oxide Film Single‑Rivet PFO Occluder Approved for Market Launch by NMPA – Novel Design Targets Residual Shunts in Patent Foramen Ovale Closure

CompanyDrug

Luzhu Biotech’s Self‑Developed Recombinant RSV Vaccine Candidate Approved for Clinical Trials by NMPA – Pre‑F Protein Antigen Advances Toward Prevention of RSV Lower Respiratory Tract Disease

- Advertisement -
Ad image
Qilu Pharmaceutical Drops RMB 400 Million Equity Stake in TYK Medicines – But TY‑9591 Licensing and China Commercialization Deal Stays Alive
CompanyDeals

Qilu Pharmaceutical Drops RMB 400 Million Equity Stake in TYK Medicines – But TY‑9591 Licensing and China Commercialization Deal Stays Alive

US Treasury Drafts China Pharma Investment Rules Likely to Preserve Licensing Deals – A Carve‑Out From Broader National‑Security Tightening
Policy / Regulatory

US Treasury Drafts China Pharma Investment Rules Likely to Preserve Licensing Deals – A Carve‑Out From Broader National‑Security Tightening

IMPACT Therapeutics and Pharmanovia Receive Positive CHMP Opinion for Sepalna (Senaparib) – PARP1/2 Inhibitor Set for EU First‑Line Ovarian Cancer Maintenance
CompanyDrug

IMPACT Therapeutics and Pharmanovia Receive Positive CHMP Opinion for Sepalna (Senaparib) – PARP1/2 Inhibitor Set for EU First‑Line Ovarian Cancer Maintenance

China's NHC Issues Landmark Rare‑Disease Notice – Mandating Province‑Wide Clinics and Quality Control Networks by End‑2026
Policy / Regulatory

China’s NHC Issues Landmark Rare‑Disease Notice – Mandating Province‑Wide Clinics and Quality Control Networks by End‑2026

Staidson Unit BioJeTay Wins NMPA Trial Acceptance for Bemiltenase alfa in Major Surgical Bleeding – First‑in‑Class Snake Venom–Derived Factor X Activator Expands Beyond Hemophilia
CompanyDrug

Staidson Unit BioJeTay Wins NMPA Trial Acceptance for Bemiltenase alfa in Major Surgical Bleeding – First‑in‑Class Snake Venom–Derived Factor X Activator Expands Beyond Hemophilia

Medicovestor Completes Seed Funding Round to Advance Next-Generation Antibody and ADC Pipeline – MC004 Naked Antibody Targets FDA IND Filing by Early 2027
CompanyDeals

Medicovestor Completes Seed Funding Round to Advance Next-Generation Antibody and ADC Pipeline – MC004 Naked Antibody Targets FDA IND Filing by Early 2027

HemaCell Therapeutics Wins NMPA Clinical Trial Clearance for World's First Stem Cell-Derived Allogeneic Platelet Injection – A Potential Leap Beyond Donor-Dependent Transfusion
Others

HemaCell Therapeutics Wins NMPA Clinical Trial Clearance for World’s First Stem Cell-Derived Allogeneic Platelet Injection – A Potential Leap Beyond Donor-Dependent Transfusion

Orbis Medicines Signs Strategic Collaboration and License Deal with Novo Nordisk – Up to $1.4 Billion to Advance Next-Generation Oral Macrocycle Cardiometabolic Therapies
CompanyDeals

Orbis Medicines Signs Strategic Collaboration and License Deal with Novo Nordisk – Up to $1.4 Billion to Advance Next-Generation Oral Macrocycle Cardiometabolic Therapies

Novo Nordisk's Once-Weekly Sogroya Wins Positive CHMP Opinion for Children with Idiopathic Short Stature – Long-Acting Growth Hormone Set to Expand Beyond GHD in Europe
CompanyDrug

Novo Nordisk’s Once-Weekly Sogroya Wins Positive CHMP Opinion for Children with Idiopathic Short Stature – Long-Acting Growth Hormone Set to Expand Beyond GHD in Europe

Novo Nordisk Acquires Three Obesity R&D Programs from Kallyope – Non-Incretin Assets Broaden the Cardiometabolic Pipeline Beyond GLP-1
CompanyDeals

Novo Nordisk Acquires Three Obesity R&D Programs from Kallyope – Non-Incretin Assets Broaden the Cardiometabolic Pipeline Beyond GLP-1

BioMarin's Vosoritide Wins NMPA Approval in China – First CNP-Analog Therapy for Pediatric Achondroplasia Enters the World's Largest Rare Bone Disease Market
CompanyDrug

BioMarin’s Vosoritide Wins NMPA Approval in China – First CNP-Analog Therapy for Pediatric Achondroplasia Enters the World’s Largest Rare Bone Disease Market

Alexion's Klygefa Recommended for EU Approval in AChR-Positive Generalized Myasthenia Gravis – AstraZeneca's Subcutaneous Nanobody C5 Inhibitor Clears Major Regulatory Hurdle
CompanyDrug

Alexion’s Klygefa Recommended for EU Approval in AChR-Positive Generalized Myasthenia Gravis – AstraZeneca’s Subcutaneous Nanobody C5 Inhibitor Clears Major Regulatory Hurdle

Show More